These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28962071)

  • 21. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
    Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
    Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
    Kuter DJ
    Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
    Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
    Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
    Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Romiplostim.
    Kuter DJ
    Cancer Treat Res; 2011; 157():267-88. PubMed ID: 21052962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    Waisbren J; Dinner S; Altman J; Frankfurt O; Helenowski I; Gao J; McMahon BJ; Stein BL
    Int J Hematol; 2017 Jan; 105(1):44-51. PubMed ID: 27558575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis.
    Wang K; Shao Y; Li C; Bao J; Zhu W; Zhou Y
    Ann Hematol; 2022 Oct; 101(10):2219-2229. PubMed ID: 35976414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
    Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
    Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
    Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerobic physical exercise for adult patients with haematological malignancies.
    Bergenthal N; Will A; Streckmann F; Wolkewitz KD; Monsef I; Engert A; Elter T; Skoetz N
    Cochrane Database Syst Rev; 2014 Nov; (11):CD009075. PubMed ID: 25386666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis.
    Meng F; Chen X; Yu S; Ren X; Liu Z; Fu R; Li L
    Front Oncol; 2020; 10():582686. PubMed ID: 33324559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
    Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
    Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
    Oliva EN; Riva M; Niscola P; Santini V; Breccia M; Giai V; Poloni A; Patriarca A; Crisà E; Capodanno I; Salutari P; Reda G; Cascavilla N; Ferrero D; Guarini A; Tripepi G; Iannì G; Russo E; Castelli A; Fattizzo B; Beltrami G; Bocchia M; Molteni A; Fenaux P; Germing U; Ricco A; Palumbo GA; Impera S; Di Renzo N; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Liberati AM; Candoni A; Delfino IM; Arcadi MT; Cufari P; Rizzo L; Bova I; D'Errigo MG; Zini G; Latagliata R
    J Clin Oncol; 2023 Oct; 41(28):4486-4496. PubMed ID: 37294914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.